Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.57 |
| ▸ | ITGAV | P06756 | 10/20 | 0.57 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 5/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835824 | 0.94 | ITGB3 (0.52) | ITGB3ITGAVADAMTS4MMP2MMP9 | |
| SCHEMBL5338635 | 0.87 | ITGB3 (0.69) | ITGB3ITGAVADAMTS4MMP2MMP9 | |
| SCHEMBL5336087 | 0.85 | ITGB3 (0.60) | ITGB3ITGAV | |
| SCHEMBL5340108 | 0.81 | ITGB3 (0.59) | ITGB3ITGAV | |
| SCHEMBL14501726 | 0.79 | ITGB3 (0.89) | ITGB3ITGAVADAMTS4 | |
| SCHEMBL5338036 | 0.79 | ITGB3 (0.89) | ITGB3ITGAVADAMTS4 | |
| SCHEMBL5339721 | 0.76 | ITGB3 (0.53) | ITGB3ITGAVADAMTS4 | |
| SCHEMBL14501729 | 0.74 | ITGB3 (0.79) | ITGB3ITGAVADAMTS4MMP2MMP9 | |
| SCHEMBL3835821 | 0.74 | ITGB3 (0.79) | ITGB3ITGAVADAMTS4MMP2MMP9 | |
| SCHEMBL5878498 | 0.73 | ITGB3 (1.00) | ITGB3ITGAVADAMTS4MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20060189544-A1 | Integrin-Mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189544-A1 | Integrin-Mediated drug targeting | ITGAV, ITGB3, ITGB1 | ITGB3 2/4885ITGAV 1/4885ADAMTS4 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.